If you''re a trend trader, consider that the strongest clear trend on the hourly chart exists on the 20 hour timeframe. The post NICE Ltd (NICE): Price Now Near $273.14; Daily Chart Shows An Uptrend on 100 Day Basis appeared first on ETF Daily News .
No summary available.
Philadelphia chose NICE Ltd''s (NASDAQ: NICE ) NICE Inform Elite& to boost emergency communications for its new 911 center slated to open in 2022. NICE''s 911-ready technology will help to improve the center''s operational Full story available on Benzinga.com
Upgrades According to Deutsche Bank, the prior rating for KLA Corp (NASDAQ: KLAC ) was changed from Hold to Buy. KLA earned $3.85 in the third quarter, compared to $2.47 in the year-ago quarter. The current stock performance of KLA shows a 52-week-high of $359.69 and a 52-week-low of $171.31. Moreover, at the end of the last trading period, the closing price was at $313.80. According to JP Morgan, the prior rating for NICE Ltd (NASDAQ: NICE ) was changed from Neutral to Overweight. NICE earned $1.54 in the first quarter, compared to $1.34 in the year-ago quarter. The stock has a 52-week-high of $288.73 and a 52-week-low of $181.76. At the end of the last trading period, NICE closed at $218.92. Credit Suisse upgraded the previous rating for Colgate-Palmolive Co (NYSE: CL ) from Neutral to Outperform. In the first quarter, Colgate-Palmolive showed an EPS of $0.80, compared to $0.75 from the year-ago quarter. The stock has a 52-week-high of $86.41 and a 52-week-low of $71.21. At the end of the last trading period, Colgate-Palmolive closed at $82.93.
If you''re a trend trader, consider that the strongest clear trend on the hourly chart exists on the 50 hour timeframe. The post NICE Ltd (NICE): Price Now Near $215.52; Daily Chart Shows Downtrend on 20 Day Basis appeared first on ETF Daily News .
NICE Ltd (NASDAQ: NICE ) and RingCentral Inc (NYSE: RNG ) have extended their multi-year agreement to market and sell RingCentral Contact Center globally to tap the … Full story available on Benzinga.com
NICE earnings call for the period ending March 31, 2021.
No summary available.
RA`ANANA, Israel (AP) _ Nice Ltd. (NICE) on Thursday reported first-quarter profit of $52.2 million. The Ra`Anana, Israel-based company said it had profit of 78 cents per share. Earnings, adjusted for one-time gains and costs, were $1.54 per share. The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment 
Analysts expect that NICE Ltd. (NASDAQ:NICE) will post earnings per share of $1.38 for the current quarter, Zacks reports. Four analysts have provided estimates for NICE’s earnings, with the lowest EPS estimate coming in at $1.36 and the highest estimate coming in at $1.40. NICE posted earnings of $1.30 per share during the same quarter […]
NICE Ltd. (NASDAQ:NICE) has earned a consensus rating of “Hold” from the eleven ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective […]
HOBOKEN, N.J.--(BUSINESS WIRE)--NICE Ltd. (NASDAQ: NICE) (the "Company") announced today that it intends to offer, subject to market and other considerations, $400,000,000 aggregate principal amount of Convertible Senior Notes due 2025 (the "Convertible Notes") in a private placement under the Securities Act of 1933, as amended (the "Securities Act"). The Company also intends to grant to the initial purchasers of the Convertible Notes an option to purchase up to an additional $60,000,000 aggreg
The National Institute for Health and Care Excellence (NICE) last week warned that pills including paracetamol, should no longer be routinely prescribed to patients with chronic pain.
According to a new study, aspirin, ibuprofen and paracetamol, common painkillers we are used to taking for mild fever or aches and pains, may cause more harm than good in the treatment of chronic pain. In a draft guideline published on Monday, Aug. 3, the United Kingdom's National Institute for Health and Care Excellence (Nice) announced that there is "little or no evidence" of the efficacy of commonly used medicines against primary chronic pain, which is defined as pain that lasts or reappears for longer than three months and is caused by physical incapacity or emotional distress. According to the announcement, analgesics don't diminish pain, improve quality of life or minimiz… Keep on reading: Common painkillers should not be used for chronic pain, study suggests
Painkillers such as paracetamol, ibuprofen, aspirin and opioids can do “more harm than good” and should not be prescribed to treat chronic pain, health officials have said. The National Institute for Health and Care Excellence (Nice) said that there was “little or no evidence” the commonly used drugs for chronic primary pain made any difference to people’s quality of life,